Contact the ACC Registration and Housing Center

  • 864-208-2670
  • M-F, 9:00 a.m. - 5:00 p.m. ET

  • Industry-Expert Theaters
    Expo, #1957 and #2455

    Connect with the experts in the Industry-Expert Theaters as presenters share the latest in cardiovascular practices, services and technologies while you enjoy refreshments or lunch — presentations are conveniently scheduled during the daily breaks.

    Quick Links: SaturdaySundayMonday

    Saturday, March 4

    10:15 – 11:15 a.m.

    4009. The Patient Journey – From Hospital, to Home, to Heart Recovery
    Industry-Expert Theater 2, #2455
    Sponsored by Abiomed

    • Underdiagnosis of CAD and CGS
    • Patient Journey: Referral for PCI, transfer for CGS: CCL, ICU, OR
    • Case based examples on CGS escalation, RHF support RP flex
    • Difference between HF and AMI CGS

    Ashley Bock, MD
    Advanced Heart Failure Specialist Director of LVAD Program

    Ann Gage, MD
    Interventional Cardiologist and Cardiac Critical Care

    Duck Nguyen, MD
    Cardiothoracic Surgeon Director of Mechanical Circulatory Support

    10:45 – 11:45 a.m.

    4001. Personalizing Patient Care Along the Heart Failure Journey
    Industry-Expert Theater 1, #1957
    Sponsored by Abbott

    Heart failure is a complex and progressive disease, so it is important to have a multi-step management plan for these patients. In this program, experts will discuss Abbott's unique product portfolio that provides for lifetime management of Heart Failure. Featured in this discussion will be MitraClip™ Therapy and the CardioMEMS™ HF System, including recent studies that showed how the CardioMEMS™ HF System was able to measure the hemodynamic impact in patients that received TEER therapy.

    Matthew J. Price, MD
    Clinical Professor of Medicine
    Director, Cardiac Catheterization Laboratory
    Division of Cardiovascular Diseases, Scripps Clinic

    Ajay Srivastava, MD, FACC
    Advanced Heart Failure and Transplant Cardiology
    Division of Cardiovascular Diseases, Scripps Clinic

    Shashank S. Desai, MD, MBA
    Director, Inova Thoracic Transplant
    Director, Strategy and Growth Inova Heart & Vascular Institute

    12:45 – 1:45 p.m.

    4002. Elevated Lipoprotein(a): Raise Your Game and Lower Your (Risk) Score?
    Industry-Expert Theater 1, #1957
    Sponsored by Novartis Pharmaceuticals Corporation

    A disease state (non-CME), interactive Expert Panel presentation and discussion on lipoprotein(a) – the expert panelists will share information and data on a number of clinically relevant topics and demonstrate why elevated Lp(a) is a risk enhancer for ASCVD.

    Nathan D. Wong, PhD, MPH
    Professor and Director
    UCI Heart Disease Prevention Program
    University of California, Irvine School of Medicine
    Irvine, CA

    Leslie J. Donato, PhD
    Assistant Professor and Clinical Chemist
    Department of Laboratory Medicine and Pathology
    Mayo Clinic
    Rochester, MN

    Leslee J. Shaw, PhD, FACC
    Department of Medicine (Cardiology), Population Health Science and Policy, and Obstetrics, Gynecology and Reproductive Science
    Mount Sinai Icahn School of Medicine
    New York, NY

    Emily E. Brown, MGC, CGC
    Genetic Counselor
    Center for Inherited Heart Disease
    The Johns Hopkins University School of Medicine
    Baltimore, MD

    Patient Perspective
    Speaker: Maurice Williams, PhD, MPH
    Medical Science Liaison,
    Associate Director
    IM US Medical Affairs
    Novartis Pharmaceuticals Corporation
    East Hanover, NJ

    4010. Breaking the Cycle of Recurrent Pericarditis: A Targeted Approach For Pain Relief, Inflammation Resolution and Flare Prevention
    Industry-Expert Theater 2, #2455
    Sponsored by Kiniksa Pharmaceuticals

    For many patients, single- or first-episode pericarditis is just the beginning of their journey. Up to 30% of patients with pericarditis will experience a recurrent episode within 18 months, despite treatment with traditional therapies. Managing recurrent pericarditis (RP) can be a challenge for clinicians because pericarditis and RP are distinctly different in pathology, duration of disease, and risk of both recurrence and complications. At this Industry Expert Theater, we will review the diagnosis of RP, the underlying interleukin-1 (IL-1) pathway that drives the repetitive cycle of recurrence, insights regarding RP disease duration, and a treatment option for RP.

    Robert W. W. Biederman, MD, FACC, FAHA, FSGC, FASA, FSCMR
    Professor of Medicine Allegheny General Hospital/Temple University College of Medicine
    Adjunct Professor of Medicine Carnegie Mellon University, Department of Bioengineering
    Systems Director, Cardiovascular Imaging Allegheny General Hospital/AHN
    Professor, Department of Medicine Drexel University College of Medicine

    3:15 – 4:15 p.m.

    4003. ACC Recommends Lower LDL-C Thresholds For ASCVD Patients at Risk For CV Events
    Industry-Expert Theater 1, #1957
    Sponsored by Amgen

    In this presentation we will discuss the new recommendation from the 2022 ACC Consensus Pathway around a lower LDL-C threshold for patients with ASCVD at very high risk for CV Events.

    Payal Kohli, MD, FACC

    4011. Jardiance® (empagliflozin) Tablets: A Review of the Latest Data
    Industry-Expert Theater 2, #2455
    Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC

    This program will review recent clinical trial data for JARDIANCE. It will also provide information on JARDIANCE initiation and dosing, as well as guidance for monitoring patients on JARDIANCE. Attendees will have the opportunity to ask the faculty questions about the data presented.

    Javed Butler, MD, MPH, MBA
    President, Baylor Scott & White Research Institute
    Senior Vice President, Baylor Scott & White Health Distinguished
    Professor of Medicine, University of Mississippi Dallas, Texas

    Chief Scientific Officer, Flourish Research
    Clinical Affiliate Professor of Cardiology, Charles E. Schmidt College of Medicine, Florida Atlantic University

    Daniel Bensimhon, MD
    Medical Director, Advanced HF & Mechanical Circulatory Support Program at Cone Health
    Greensboro, North Carolina

    Karol E. Watson, MD, PhD
    Professor of Medicine, Department of Cardiology, David Geffen School of Medicine University of California, Los Angeles

    Sunday, March 5

    9:15 – 10:15 a.m.

    4004. Recognizing the Underrecognized: Transthyretin Cardiac Amyloidosis, a Potential Underlying Cause of Heart Failure
    Industry-Expert Theater 1, #1957
    Sponsored by Pfizer

    Transthyretin amyloid cardiomyopathy (or ATTR-CM) is a serious, underrecognized and underdiagnosed cause of heart failure. Early recognition of clinical clues and accurate diagnosis are crucial to starting patients on the appropriate continuum of care. Join us to help raise awareness of the signs and symptoms of ATTR-CM, and the role of cardiac health professionals in suspecting, diagnosing and confirming ATTR-CM. The program will end with a review of the clinical data supporting an oral treatment option for patients with this progressive disease.

    Barry Trachtenberg, MD, FACC
    Co-Director, Bradley Z Naifeh Amyloidosis Program at Houston Methodist J.C. Walter Jr. Transplant Center
    Affiliate, Houston Methodist DeBakey Heart and Vascular Center
    Co-Chair of Heart Failure Section, Texas Chapter of American College of Cardiology
    Houston, TX

    4012. Is LEQVIO® (inclisiran) an Attractive Therapy? What Makes it Different?
    Industry-Expert Theater 2, #2455
    Sponsored by Novartis Pharmaceuticals Corporation

    This program will discuss key aspects that make LEQVIO compelling and explore scenarios and considerations that make it well suited for patients with ASCVD with elevated LDL-C who may need something more, despite their best efforts with diet and maximally tolerated statin. Don't miss the deep dive into the mechanism of action, dosing schedule, administration, clinical efficacy, and safety data.

    Jason Lecocq, MD, MBA
    Senior Medical Director, Atherosclerosis
    US Clinical Development & Medical Affairs
    Cardiovascular & Metabolism, Novartis Pharmaceuticals Corporation

    11:15 a.m. – 12:15 p.m.

    4005. A Focus on Lipoproteins: Understanding Established and Emerging Cardiovascular Risk Factors in Patients With ASCVD
    Industry-Expert Theater 1, #1957
    Sponsored by Amgen

    Come join Dr. Baber and Dr. Taub as they discuss established and emerging cardiovascular risk factors in patients with ASCVD.

    Usman Baber, MD, MS, FACC, FSCAI
    Associate Professor of Medicine (Cardiology)
    Director, Interventional Cardiology Fellowship and Cardiac Catheterization Laboratory
    University of Oklahoma Health Sciences Center

    Pam Taub, MD, FACC, FASPC
    Professor of Medicine (Cardiology)
    Founder and Director, Step Family Cardiac Wellness and Rehabilitation Center
    University of California, San Diego

    4013. A Next Step in LDL-C–Lowering Therapy: Oral Nonstatin Therapies
    Industry-Expert Theater 2, #2455
    Sponsored by Esperion Therapeutics, Inc.

    The session will cover the following information:

    • Atherosclerotic cardiovascular disease and lipid management
    • Unique mechanism of action for two treatment options
    • Efficacy data for two treatment options
    • Safety data for two treatment options

    Kausik Ray, BSc, MBChB, FRCP, FRCP, MD, MPhil, FACC, FESC, FAHA
    Professor of Public Health and Honorary Consultant Cardiologist, President European Atherosclerosis Society, Imperial College London

    3:30 – 4:30 p.m.

    4006. Left Atrial Appendage Closure For Stroke Risk Reduction: New Data, New Insights
    Industry-Expert Theater 1, #1957
    Sponsored by Boston Scientific

    This session will cover:

    • Evolution of LAAC: Where are we now?
    • Anticoagulation and device-based therapies: stroke risk, bleed risk, and what matters to patients
    • What will happen with LAAC over the next decade? A peek into the future

    Vivek Reddy, MD
    Christine Chung, MD
    Sean Pokorney, MD, MBA
    Payal Kohli, MD

    4014. Transforming Hypertension Management With Ultrasound Renal Denervation
    Industry-Expert Theater 2, #2455
    Sponsored by ReCor Medical

    Please join this program if you want to:

    • Learn the latest clinical evidence and the unique benefits of Ultrasound Renal Denervation (uRDN) Therapy
    • Understand perspectives on patient selection
    • Learn how to establish interventional hypertension therapy

    Daichi Shimbo, MD
    Ajay Kirtane, MD
    Michael Bloch, MD
    Andrew Sharp, PhD

    Monday, March 6

    9:45 – 10:45 a.m.

    4007. Advances in Technology For Managing Patients Across the Spectrum of Acute Cardiac Care
    Industry-Expert Theater 1, #1957
    Sponsored by ZOLL

    This session will cover:

    • ZOLL Arrhythmia Management System (AMS) and the MAPS trial
    • Using AMS and the LifeVest in Routine Practice
    • Patient Management of Acute Cardiac Patients and screening for sleep apnea with WatchPA

    Harish Manyam, MD
    Chief of Cardiology, Erlanger Heart and Lung Institute Head of Electrophysiology Associate Professor of Medicine, University of Tennessee Chattanooga, TN

    Josh Montgomery, PA

    Katie Minor, NP

    4015. Worsening Heart Failure in Patients With Symptomatic Chronic HFrEF: Will You Recognize the Early Downward Trajectory?
    Industry-Expert Theater 2, #2455
    Sponsored by Cytokinetics

    During this presentation, we will review the downward trajectory of worsening heart failure in patients with symptomatic chronic HFrEF. We will discuss the burden of worsening heart failure and current treatment strategies. We will also explore the challenges posed by worsening signs or symptoms in high-risk patients, and share best practice considerations to identify early signs or symptoms.

    Stephen J. Greene, MD, FACC, FHSA
    Division of Cardiology, Duke University School of Medicine and Duke Clinical Research Institute

    James Januzzi, MD, FACC, FESC
    Hutter Family Professor of Medicine, Harvard Medical School; Cardiology Division, Massachusetts General Hospital; Director of Heart Failure and Biomarker Trials, Baim Institute for Clinical Research

    Robert Mentz, MD, FHFSA, FACC
    Chief, Heart Failure Section, Duke University Medical Center; Associate Program Director, Duke Cardiovascular Disease Fellowship; Editor-in-Chief, Journal of Cardiac Failure, Official Journal of the HFSA

    12:15 – 1:15 p.m.

    4008. Addressing the Risk of Early Recurrent MI: The Evolving Role of HDL in the 90-Day Post-AMI High-Risk Period
    Industry-Expert Theater 1, #1957
    Sponsored by CSL Behring

    Could cholesterol efflux have the potential to reduce the high risk of recurrent CV events in the 90-day window following an AMI? Join our expert faculty of Dr. Eliot Brinton and Dr. Nihar Desai for discussion on the potential link between cholesterol efflux and the clinical importance of the high‑risk 90-day period following an AMI. The session will highlight risk of early recurrence of cardiovascular events despite advances in SOC, as well as explore current understanding of cholesterol efflux to potentially improve CV outcomes. We look forward to welcoming you to a lively, informative and interactive discussion.

    Eliot Brinton, MD
    President Utah Lipid Center, USA

    Nihar Desai, MD, MPH
    Associate Professor, Yale School of Medicine,
    Associate Chief of the Section of Cardiovascular Medicine, Yale New Haven Health System, USA

    4016. Time For CHANGE: Rethinking Rhythm Control to Improve Outcomes in AF
    Industry-Expert Theater 2, #2455
    Sponsored by Sanofi

    Now recognized as a chronic disease requiring an integrated, life-long management strategy, timely restoration and maintenance of sinus rhythm in atrial fibrillation (AF) is emerging as a key component in improving outcomes. Clinical trial data and real-world studies strengthen a growing body of evidence that suggests early rhythm control is associated with improved cardiovascular outcomes, better quality of life, and reduced hospitalization. Join our distinguished panel of experts as they discuss the latest data, updated guideline recommendations, and how new trials are addressing the question of early rhythm control and first-detected AF.

    Pam Taub, MD, FACC, FASPC (Chair)
    Director of Step Family Foundation
    Cardiovascular Rehabilitation and Wellness Center
    Professor of Medicine
    UC San Diego Health System Division of Cardiovascular Medicine
    San Diego, California

    Jonathan Piccini, MD, MHS, FHRS
    Associate Professor of Medicine
    Director, Cardiac Electrophysiology
    Duke University
    Durham, North Carolina

    Jagmeet P. Singh, MD, ScM, PhD
    Professor of Medicine
    Massachusetts General Hospital and Harvard Medical School
    Boston, Massachusetts

    Information current as of March 2, 2023.

    Industry-Expert Theater presentations are not part of ACC.23/WCC, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

    American College of Cardiology

    © 2023 American College of Cardiology Foundation. Visit

    Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Cookie Policy Contact Us